YILDIZ, R. Et Al. 2012. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.11 , 1845-1852.

YILDIZ, R., Benekli, M., ÖZKAN, M., Alkis, N., Berk, V., Kaplan, M. A., ... Ciltas, A.(2012). Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.11, 1845-1852.

YILDIZ, RAMAZAN Et Al. "Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.11, 1845-1852, 2012

YILDIZ, RAMAZAN Et Al. "Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.11, pp.1845-1852, 2012

YILDIZ, R. Et Al. (2012) . "Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.11, pp.1845-1852.

@article{article, author={RAMAZAN YILDIZ Et Al. }, title={Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2012, pages={1845-1852} }